Artelo Biosciences, Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted, dilution-weighted asset value: $4.2M cash plus an estimated $1.5M risk-adjusted early-stage cannabinoid-therapeutics pipeline value, divided by a share count grossed up ~1.7x (547.77K shares) to reflect the near-certain near-term dilutive financing implied by a -$12.67M annual cash burn against only $4.2M of cash; ≈$6.12/share.

Reasoning: Artelo's cash burn far exceeds its cash on hand, implying imminent financing and substantial dilution, so a standard DCF would be misleading; explicitly discounting for expected share-count dilution alongside a heavily risk-adjusted pipeline value better reflects the economic reality facing current shareholders.